Team:EPF Lausanne/Calendar/16 September 2013

From 2013.igem.org

(Difference between revisions)
 
(4 intermediate revisions not shown)
Line 1: Line 1:
{{Template:EPFL2013Header}}
{{Template:EPFL2013Header}}
 +
<font size = "4"> Cell Surface Display </font> <BR>
-
Sensing <BR>
+
''Western Blot'' <BR>
 +
Using the samples inoculated the Day before, we started a Western blot experiment to prove the expression of our constructs. For this reaction, we used the anti-streptavidin FITC conjugated antibody.
 +
<br>- The Streptavidin Alive initial plasmid transformed cells were used as positive control and competent cells as negative control.
 +
<br>- We finished the experiment the same day because using this antibody we could directly watch the membrane with a typhoon scanner after the first staining step.
 +
''New strategy''<BR>
 +
<br>- The first try to assemble the parts of the new strategy didn't succeed. Checked again all the primers, to make sure we didn't made a mistake in the design.<br>
-
'''Seuqencing of the hya promoter plasmid''' <BR>
+
<font size = "4"> Sensing-Effector </font> <BR>
-
I send the newly isolated and purified hya-containing plasmid for sequencing.
+
-
'''Transformation'''
+
''Sequencing of the hya promoter plasmid'' <BR>
-
Because the functional assays of the sensing module were inconclusive, I decided to do another transformation with the Plasmids that I had sent for sequencing and whose results showed that the promoters were really present, namely the cad-promoter and the constitutive promoter from iGEM.
+
-I send the newly isolated and purified hya-containing plasmid for sequencing.
 +
''Transformation''<BR>
 +
-Because the functional assays of the sensing module were inconclusive, I decided to do another transformation with the Plasmids that I had sent for sequencing and whose results showed that the promoters were really present, namely the cad-promoter and the constitutive promoter from iGEM.
 +
<BR><BR>
 +
<font size = "4"> Nanoparticles</font> <BR>
-
'''Nanoparticles'''
+
''MMP2 digestion assays'' <BR>
-
 
+
-
MMP2 digestion assays  
+
{{Template:EPFL2013Footer}}
{{Template:EPFL2013Footer}}

Latest revision as of 22:51, 4 October 2013

Taxi.Coli: Smart Drug Delivery iGEM EPFL

Header

Cell Surface Display

Western Blot
Using the samples inoculated the Day before, we started a Western blot experiment to prove the expression of our constructs. For this reaction, we used the anti-streptavidin FITC conjugated antibody.
- The Streptavidin Alive initial plasmid transformed cells were used as positive control and competent cells as negative control.
- We finished the experiment the same day because using this antibody we could directly watch the membrane with a typhoon scanner after the first staining step. New strategy

- The first try to assemble the parts of the new strategy didn't succeed. Checked again all the primers, to make sure we didn't made a mistake in the design.

Sensing-Effector

Sequencing of the hya promoter plasmid
-I send the newly isolated and purified hya-containing plasmid for sequencing.

Transformation
-Because the functional assays of the sensing module were inconclusive, I decided to do another transformation with the Plasmids that I had sent for sequencing and whose results showed that the promoters were really present, namely the cad-promoter and the constitutive promoter from iGEM.

Nanoparticles

MMP2 digestion assays